Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 44%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences is poised for continued success, with strong performance in their core revenue segments and solid earnings growth. Their recent 2Q results beat expectations and led to an increase in their revenue outlook for FY26. Despite difficult 2H comps, the company is maintaining its growth trajectory and has potential for further expansion through new product launches and opportunities in adjacent markets. Their strong financials, innovative products, and sustainable practices make them a clear leader in the competitive medical device industry.

Bears say

Edwards Lifesciences is currently experiencing growth in revenue in key products, including TAVR and TMTT. However, potential growth headwinds driven by macro factors, slower adoption of TAVR, and increased competition could hinder the company's overall performance. Furthermore, there is a risk for potential setbacks in R&D efforts or clinical trials, as well as external factors such as staffing shortages that could impact the company's financials. These risks could lead to a downside scenario for the stock and should be closely monitored by investors.

Edwards Lifesciences (EW) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 44% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 18 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.